Phase 1/2 Study of ONO-4538 in Japanese Participants with Sepsis or Septic Shock
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 May 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Sepsis; Septic shock
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2017 New trial record